Showing results (71-80 of 91) with videos related to

Sort By:
Pageof 10
International Journal of Urology : Official Journal of the Japanese Urological Association|December 14, 2020
Impact of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma receiving systemic tyrosine kinase inhibitor therapy: A multicenter retrospective studyShingo Hatakeyama, Sei Naito, Kazuyuki Numakura, et al.
International Journal of Clinical Oncology|September 22, 2023
Preoperative prognostic model for localized and locally advanced renal cell carcinoma: Michinoku Japan Urological Cancer Study GroupShigemitsu Horie, Sei Naito, Shingo Hatakeyama, et al.
International Journal of Clinical Oncology|January 1, 2022
Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era - a multi-institutional retrospective studyRenpei Kato, Sei Naito, Kazuyuki Numakura, et al.
Urologic Oncology|September 21, 2021
External validation of the REMARCC model for the selection of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma: A multicenter retrospective studyKazutaka Okita, Shingo Hatakeyama, Sei Naito, et al.
Cancer Medicine|October 31, 2023
The efficacy of molecular targeted therapy and nivolumab therapy for metastatic non-clear cell renal cell carcinoma: A retrospective analysis using the Michinoku Japan urological cancer study group databaseTomoyuki Koguchi, Sei Naito, Shingo Hatakeyama, et al.
Cancer Medicine|July 27, 2021
Outcomes of axitinib versus sunitinib as first-line therapy to patients with metastatic renal cell carcinoma in the immune-oncology eraKazuyuki Numakura, Yumin Muto, Sei Naito, et al.
Cancer Medicine|October 6, 2022
Clinical impact of early response to first-line VEGFR-TKI in patients with metastatic renal cell carcinoma on survival: A multi-institutional retrospective studyRyuta Sobu, Kazuyuki Numakura, Sei Naito, et al.
International Journal of Clinical Oncology|May 13, 2020
Efficacy and safety of nivolumab for renal cell carcinoma in patients over 75 years old from multiple Japanese institutesKazuyuki Numakura, Mizuki Kobayashi, Shingo Hatakeyama, et al.
International Journal of Clinical Oncology|February 14, 2025
Characteristics of patients with metastatic renal cell carcinoma who do not respond to axitinib treatmentKojiro Ohba, Takahiro Osawa, Takahiro Kojima, et al.
Anticancer Research|November 1, 2023
Second-line Pembrolizumab for Metastatic Urothelial Carcinoma: Differences in Treatment Outcomes According to the Primary SiteNaotaka Nishiyama, Yuki Kita, Katsuhiro Ito, et al.
Pageof 10